AI Portfolio Summary
In 2025 Q4, ACORN CAPITAL ADVISORS, LLC maintained a portfolio of 21 distinct positions. The most significant new addition to the portfolio was ATHIRA PHARMA INC., which now represents 1.29% of the total fund value. They heavily accumulated shares in UROGEN PHARMA LTD, increasing their position by 15.0%. Conversely, ACORN CAPITAL ADVISORS, LLC completely exited their position in VYNE THERAPEUTICS IN.
Total Positions
21
Quarter
2025 Q4
Top Holding
TERN (23.9%)
Top 10 Concentration
88.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-21 of 21
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TERN
TERNS PHARMACEU...
|
Healthcare | 23.90% | 7.52% |
#1
4
Prev: #5
|
6.5 | -225,000 | -11.4% |
P
S
|
1,746,264 | $70,549,066 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 15.92% | 23.14% |
#2
1
Prev: #1
|
6.5 | no change | no change |
P
S
|
1,131,501 | $46,979,903 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 11.49% | 12.76% |
#3
1
Prev: #2
|
7.0 | 188,671 | 15.0% |
P
S
|
1,448,420 | $33,921,996 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 9.10% | 9.96% |
#4
Prev: #4
|
5.1 | no change | no change |
P
S
|
2,144,844 | $26,853,447 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PBYI
PUMA BIOTECHNOL...
|
Healthcare | 8.33% | 11.14% |
#5
2
Prev: #3
|
4.8 | no change | no change |
P
S
|
4,131,299 | $24,581,229 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CADL
CANDEL THERAPEU...
|
Healthcare | 4.94% | 6.68% |
#6
Prev: #6
|
3.0 | no change | no change |
P
S
|
2,580,517 | $14,579,921 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Healthcare | 4.36% | 2.19% |
#7
4
Prev: #11
|
4.7 | 838,629 | 114.2% |
P
S
|
1,573,023 | $12,873,935 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 3.84% | 3.49% |
#8
2
Prev: #10
|
4.5 | 689,655 | 88.5% |
P
S
|
1,469,153 | $11,341,861 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 3.67% | 5.16% |
#9
2
Prev: #7
|
2.5 | no change | no change |
P
S
|
643,382 | $10,828,113 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARA
PROTARA THERAPE...
|
Healthcare | 3.16% | 3.87% |
#10
1
Prev: #9
|
2.3 | no change | no change |
P
S
|
1,752,115 | $9,338,773 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OKUR
ONKURE THERAPEU...
|
Healthcare | 2.79% | 3.96% |
#11
3
Prev: #8
|
2.1 | no change | no change |
P
S
|
2,839,674 | $8,235,055 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRDF
CARDIF ONCOLOGY...
|
Healthcare | 1.87% | 2.05% |
#12
Prev: #12
|
1.7 | no change | no change |
P
S
|
1,962,084 | $5,513,456 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LONA
ATHIRA PHARMA I...
|
Healthcare | 1.29% | — |
#13
Prev: #—
|
4.0 | 501,739 | no change |
NEW
|
501,739 | $3,798,164 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JSPR
JASPER THERAPEU...
|
Healthcare | 1.11% | 1.67% |
#14
1
Prev: #15
|
2.9 | 403,852 | 29.2% |
P
S
|
1,786,492 | $3,269,280 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 1.10% | 1.87% |
#15
2
Prev: #13
|
1.4 | no change | no change |
P
S
|
595,744 | $3,246,805 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WHWK
WHITEHAWK THERA...
|
Healthcare | 0.93% | 1.10% |
#16
Prev: #16
|
1.4 | no change | no change |
P
S
|
1,139,363 | $2,757,258 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAB
BIOATLA INC
|
Healthcare | 0.93% | 1.69% |
#17
3
Prev: #14
|
1.4 | no change | no change |
P
S
|
4,835,111 | $2,756,013 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QTTB
Q32 BIO INC.
|
Healthcare | 0.56% | 0.81% |
#18
1
Prev: #17
|
0.2 | -310,000 | -38.6% |
P
S
|
493,425 | $1,638,171 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
X4 PHARMACEUTIC...
|
—
|
Unknown | 0.37% | 0.47% |
#19
1
Prev: #18
|
1.1 | no change | no change |
P
S
|
273,349 | $1,093,398 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
ACRV
ACRIVON THERAPE...
|
Healthcare | 0.33% | 0.37% |
#20
1
Prev: #19
|
1.1 | no change | no change |
P
S
|
405,237 | $976,622 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VYNE
VYNE THERAPEUTI...
|
Healthcare | 0.00% | 0.10% |
#21
1
Prev: #20
|
0.0 | -585,147 | -99.8% |
P
S
|
1,425 | $827 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-21 of 21 holdings